Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280358 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.
A Phase 1 study, sponsored by Dey.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00280358: Completed Phase 1 study, sponsored by Dey.
NCT00280358 is a Phase 1 study that has completed, run by Dey. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00280358, a Phase 1 study, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of the study is to obtain initial pharmacokinetic data in healthy patients after dosing a combination of the study medications.
Interventions
- DRUG Formoterol Fumarate
- DRUG Fluticasone Propionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Est. Completion | 2005-12 |
| Phase | Phase 1 |
What the finished NCT00280358 record still lists
NCT00280358 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Formoterol Fumarate is the first listed.
NCT00280358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00280358 about?
NCT00280358 is a clinical study titled "A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.". The purpose of the study is to obtain initial pharmacokinetic data in healthy patients after dosing a combination of the study medications.
What is the current status of trial NCT00280358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00280358?
The interventions under investigation include: Formoterol Fumarate (DRUG), Fluticasone Propionate (DRUG).
Who is sponsoring clinical trial NCT00280358?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00280358's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer